NYSE:LLY

Eli Lilly and Stock Forecast, Price & News

$324.71

+0.48 (+0.15%)

(As of 07/1/2022 12:00 AM ET)

Add

Compare

Today's Range: $317.76
▼
$325.40
50-Day Range: $282.83
▼
$327.27
52-Week Range: $220.20
▼
$330.85

Volume: 1.82 million shs
Average Volume: 3.01 million shs
Market Capitalization: $308.53 billion

P/E Ratio: 48.11
Dividend Yield: 1.21%
Price Target: $311.65

Eli Lilly and Stock Forecast (MarketRank)

Analyst Rating: Moderate Buy
2.82 Rating Score
Upside/Downside: 4.0% Downside
$311.65 Price Target
Short Interest: Healthy
0.54% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.25
Upright™ Environmental Score
News Sentiment: 0.21
Based on 26 Articles This Week
Insider Trading: Selling Shares
$355.89 M Sold Last Quarter
Proj. Earnings Growth: 14.75%
From $8.27 to $9.49 Per Share

Overall MarketRank^™

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.05 out of 5 stars

Medical Sector

79th out of 1,429 stocks

Pharmaceutical Preparations Industry

28th out of 682 stocks

1.4 Analyst's Opinion

Consensus Rating
Eli Lilly and has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 14 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $311.65, Eli Lilly and has a forecasted downside of 4.0% from its current price of $324.71.
Amount of Analyst Coverage
Eli Lilly and has only been the subject of 3 research reports in the past 90 days.

5.0 Short Interest

Percentage of Shares Shorted
0.54% of the float of Eli Lilly and has been sold short.
Short Interest Ratio / Days to Cover
Eli Lilly and has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eli Lilly and has recently decreased by 16.21%, indicating that investor sentiment is improving significantly.

3.3 Dividend Strength

Dividend Yield
Eli Lilly and pays a meaningful dividend of 1.21%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Eli Lilly and has been increasing its dividend for 8 years.
Dividend Coverage
The dividend payout ratio of Eli Lilly and is 58.07%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 41.31% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.

3.3 Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Eli Lilly and has received a 56.49% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Peptide analogs", "Pemetrexed", "Insulin", and "SGLT2 inhibitors" products. See details.
Environmental Sustainability
The Environmental Impact score for Eli Lilly and is -2.25.

2.3 News and Social Media Coverage

News Sentiment
Eli Lilly and has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 26 news articles for Eli Lilly and this week, compared to 18 articles on an average week.
Social Mentions This Week
MarketBeat has tracked 2 reddit mentions for Eli Lilly and this week, compared to 1 mention on an average week.
Search Interest
95 people have searched for LLY on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.
MarketBeat Follows
Only 49 people have added Eli Lilly and to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eli Lilly and insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $355,891,104.00 in company stock.
Percentage Held by Insiders
Only 0.12% of the stock of Eli Lilly and is held by insiders.
Percentage Held by Institutions
82.75% of the stock of Eli Lilly and is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Eli Lilly and are expected to grow by 14.75% in the coming year, from $8.27 to $9.49 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eli Lilly and is 48.11, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 47.18.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eli Lilly and is 48.11, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 42.02.
Price to Earnings Growth Ratio
Eli Lilly and has a PEG Ratio of 2.26. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Eli Lilly and has a P/B Ratio of 33.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

30 days | 90 days | 365 days | Advanced Chart

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Stock News Headlines

July 2, 2022 | americanbankingnews.com

Eli Lilly and (NYSE:LLY) Upgraded by StockNews.com to Strong-Buy

July 1, 2022 | finance.yahoo.com

The U.S. bets billions of dollars on better COVID-19 boosters as it prepares for a spike in COVID-19 cases in the coming months

July 1, 2022 | uk.finance.yahoo.com

Where next for the Eli Lilly and Co share price?

June 30, 2022 | finance.yahoo.com

Dow Jones Futures Dive Ahead Of Key Inflation Report

June 29, 2022 | americanbankingnews.com

Eli Lilly and Company (LLY) to Issue Quarterly Dividend of $0.98 on September 9th

June 29, 2022 | seekingalpha.com

Lilly to supply additional 150K doses of COVID-19 antibody therapy to U.S.

June 29, 2022 | markets.businessinsider.com

Lilly To Supply Addl. 150K Doses Of Bebtelovimab To U.S. Government For About $275 Mln

June 29, 2022 | marketwatch.com

Eli Lilly Gets $275 Million U.S. Pact for Covid-19 Antibody Drug >LLY

June 29, 2022 | investing.com

Eli Lilly to supply additional doses of COVID antibody drug to U.S.

June 29, 2022 | americanbankingnews.com

Eli Lilly and Company (NYSE:LLY) Major Shareholder Lilly Endowment Inc Sells 41,857 Shares

June 28, 2022 | finance.yahoo.com

Novartis Will Cut 8,000 Jobs Under CEO’s Shake-Up Plan

June 28, 2022 | americanbankingnews.com

Eli Lilly and Company (NYSE:LLY) Major Shareholder Lilly Endowment Inc Sells 215,000 Shares

June 27, 2022 | finance.yahoo.com

Lilly Declares Third-Quarter 2022 Dividend

See More Headlines

About Eli Lilly and (NYSE:LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:LLY
CUSIP: 53245710
CIK: 59478
Web: www.lilly.com
Phone: (317) 276-2000
Fax: 317-276-4878
Employees: 35,000
Year Founded: 1876

Company Calendar

Last Earnings: 4/28/2022
Ex-Dividend for 6/10 Dividend: 5/13/2022
Dividend Payable: 6/10/2022
Today: 7/02/2022
Next Earnings (Estimated): 8/02/2022
Fiscal Year End: 12/31/2022

Price Target and Rating

Average Stock Price Forecast: $311.65
High Stock Price Forecast: $369.00
Low Stock Price Forecast: $264.00
Forecasted Upside/Downside: -4.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.82352941176471
Research Coverage: 17 Analysts

Profitability

EPS (Most Recent Fiscal Year): $6.75
Trailing P/E Ratio: 48.11
Forward P/E Ratio: 39.26
P/E Growth: 2.26
Net Income: $5.58 billion
Net Margins: 20.90%
Pretax Margin: 22.96%
Return on Equity: 97.58%
Return on Assets: 16.92%

Debt

Debt-to-Equity Ratio: 1.60
Current Ratio: 1.27
Quick Ratio: 0.98

Sales & Book Value

Annual Sales: $28.32 billion
Price / Sales: 10.89
Cash Flow: $9.37 per share
Price / Cash Flow: 34.67
Book Value: $9.57 per share
Price / Book: 33.93

Miscellaneous

Outstanding Shares: 950,160,000
Free Float: 949,020,000
Market Cap: $308.53 billion
Optionable: Optionable
Beta: 0.40

Social Links

Eli Lilly and Frequently Asked Questions

Should I buy or sell Eli Lilly and stock right now?: 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and or view top-rated stocks.
What is Eli Lilly and's stock price forecast for 2022?: 17 Wall Street research analysts have issued 1-year target prices for Eli Lilly and's stock. Their LLY stock forecasts range from $264.00 to $369.00. On average, they anticipate Eli Lilly and's stock price to reach $311.65 in the next twelve months. This suggests that the stock has a possible downside of 4.0%.
View analysts' price targets for Eli Lilly and or view top-rated stocks among Wall Street analysts.
How has Eli Lilly and's stock performed in 2022?: Eli Lilly and's stock was trading at $276.22 at the beginning of the year. Since then, LLY stock has increased by 17.6% and is now trading at $324.71.
View the best growth stocks for 2022 here.
When is Eli Lilly and's next earnings date?: Eli Lilly and is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Eli Lilly and.
How were Eli Lilly and's earnings last quarter?: Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings results on Thursday, April, 28th. The company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.30. The business had revenue of $7.81 billion for the quarter, compared to analysts' expectations of $7.29 billion. Eli Lilly and had a trailing twelve-month return on equity of 97.58% and a net margin of 20.90%. The firm's revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.87 EPS.
View Eli Lilly and's earnings history.
How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?: Eli Lilly and announced a quarterly dividend on Monday, June 27th. Stockholders of record on Monday, August 15th will be paid a dividend of $0.98 per share on Friday, September 9th. This represents a $3.92 annualized dividend and a yield of 1.21%. The ex-dividend date of this dividend is Friday, August 12th.
View Eli Lilly and's dividend history.
Is Eli Lilly and a good dividend stock?: Eli Lilly and(NYSE:LLY) pays an annual dividend of $3.92 per share and currently has a dividend yield of 1.21%. Eli Lilly and has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Eli Lilly and is 58.07%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 41.31% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.
How will Eli Lilly and's stock buyback program work?: Eli Lilly and announced that its Board of Directors has initiated a stock buyback program on Monday, May 3rd 2021, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.
What guidance has Eli Lilly and issued on next quarter's earnings?: Eli Lilly and updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $8.15-$8.30 for the period, compared to the consensus earnings per share estimate of $8.19. The company issued revenue guidance of $28.80 billion-$29.30 billion, compared to the consensus revenue estimate of $26.80 billion.
Who are Eli Lilly and's key executives?: Eli Lilly and's management team includes the following people:
Mr. David A. Ricks, Chairman, CEO & Pres (Age 54, Pay $4.1M) (LinkedIn Profile)
Ms. Anat Ashkenazi, Sr. VP & CFO (Age 49, Pay $1.91M)
Dr. Daniel M. Skovronsky M.D., Ph.D., Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs (Age 48, Pay $2.16M) (LinkedIn Profile)
Mr. Diogo Rau, Sr. VP & Chief Information and Digital Officer
Mr. Jacob S. Van Naarden, Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology (Age 37, Pay $2.01M)
Mr. Donald A. Zakrowski, Chief Accounting Officer & VP of Fin. (LinkedIn Profile)
Mr. Martin Bott MIBS, VP of Fin. & Special Projects (Age 59)
Kevin Hern, VP of Investor Relations
Ms. Anat Hakim J.D., Sr. VP, Gen. Counsel & Sec. (Age 53)
Mr. Alonzo Weems, Sr. VP and Chief Ethics & Compliance Officer

What is David A. Ricks' approval rating as Eli Lilly and's CEO?: 399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.
Who are some of Eli Lilly and's key competitors?: Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of LLY's competitors.
What other stocks do shareholders of Eli Lilly and own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).
What is Eli Lilly and's stock symbol?: Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
Who are Eli Lilly and's major shareholders?: Eli Lilly and's stock is owned by a variety of institutional and retail investors. Top institutional investors include Park National Corp OH (0.00%) and First Financial Bank Trust Division (0.00%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, David A Ricks, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.
Which major investors are selling Eli Lilly and stock?: LLY stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, and First Financial Bank Trust Division. Company insiders that have sold Eli Lilly and company stock in the last two years include Alfonso G Zulueta, Donald A Zakrowski, Ilya Yuffa, Lilly Endowment Inc, and Melissa S Barnes.
View insider buying and selling activity for Eli Lilly and or view top insider-selling stocks.
How do I buy shares of Eli Lilly and?: Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Eli Lilly and's stock price today?: One share of LLY stock can currently be purchased for approximately $324.71.
How much money does Eli Lilly and make?: Eli Lilly and (NYSE:LLY) has a market capitalization of $308.53 billion and generates $28.32 billion in revenue each year. The company earns $5.58 billion in net income (profit) each year or $6.75 on an earnings per share basis.
How many employees does Eli Lilly and have?: Eli Lilly and employs 35,000 workers across the globe.
Does Eli Lilly and have any subsidiaries?: The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO BioSciences Inc, ARMO Bioscience, Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma, Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Dermira, Devices for Vascular Intervention(DVI), Disarm Therapeutics, Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services Inc, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly de Centro America S.A., Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc, Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, Kinsale Financial Services Unlimited Company, Lilly (Shanghai) Management Co. Ltd, Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly China Research and Development Co. Ltd., Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Lylly Centre for Clinical Pharmacology PTE. LTD., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Pharmaserve-Lilly S.A.C.I., Physio-Control, SGX Pharmaceuticals, SGX Pharmaceuticals Inc, Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
When was Eli Lilly and founded?: Eli Lilly and was founded in 1876.
How can I contact Eli Lilly and?: Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for Eli Lilly and is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.

This page (NYSE:LLY) was last updated on 7/2/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Eli Lilly and Stock Forecast, Price & News

Eli Lilly and Stock Forecast (MarketRank)

Overall MarketRank™

1.4 Analyst's Opinion

5.0 Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

3.3 Dividend Strength

3.3 Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

2.3 News and Social Media Coverage

News Sentiment

News Coverage This Week

Social Mentions This Week

Search Interest

MarketBeat Follows

2.5 Company Ownership

1.3 Earnings and Valuation

Receive LLY Stock News and Ratings via Email

LLY Stock News Headlines

About Eli Lilly and (NYSE:LLY)

Industry, Sector and Symbol

Company Calendar

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Eli Lilly and Frequently Asked Questions

Should I buy or sell Eli Lilly and stock right now?

What is Eli Lilly and's stock price forecast for 2022?

How has Eli Lilly and's stock performed in 2022?

When is Eli Lilly and's next earnings date?

How were Eli Lilly and's earnings last quarter?

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Is Eli Lilly and a good dividend stock?

How will Eli Lilly and's stock buyback program work?

What guidance has Eli Lilly and issued on next quarter's earnings?

Who are Eli Lilly and's key executives?

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

Who are some of Eli Lilly and's key competitors?

What other stocks do shareholders of Eli Lilly and own?

What is Eli Lilly and's stock symbol?

Who are Eli Lilly and's major shareholders?

Which major investors are selling Eli Lilly and stock?

How do I buy shares of Eli Lilly and?

What is Eli Lilly and's stock price today?

How much money does Eli Lilly and make?

How many employees does Eli Lilly and have?

Does Eli Lilly and have any subsidiaries?

When was Eli Lilly and founded?

How can I contact Eli Lilly and?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™